OKYO Pharma’s OK-101 Advances in Phase 2 Trials for Dry Eye and Corneal Pain

The biopharmaceutical business OKYO Pharma Limited is making progress in creating therapeutics for two illnesses that now lack viable treatments: neuropathic corneal pain (NCP) and dry eye disease (DED). OK-101, their flagship candidate, has demonstrated encouraging outcomes in Phase 2 studies, with notable reductions in DED symptoms along with a good safety profile. In addition, the business is getting ready to start a Phase 2 trial for OK-101 in the treatment of NCP, emphasising the drug's potential to meet unmet ophthalmic medical requirements.